Harvard Bioscience Stock (NASDAQ:HBIO)

Harvard Bioscience, Inc. (HBIO) is a global provider of cutting-edge technologies, products, and services crucial for fundamental scientific investigation, drug discovery, and preclinical testing. Serving both domestic and international markets, the company supplies an extensive range of cellular and molecular instruments. This includes precision fluid handling devices like syringe and peristaltic pumps, alongside a variety of tools and accessories for tissue and organ-based laboratory research, such as surgical instruments, infusion systems, and behavioral analysis setups. Their portfolio also encompasses analytical equipment like spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis units, and electroporation/electrofusion instruments. Moreover, Harvard Bioscience specializes in developing and manufacturing advanced scientific measuring instrumentation, featuring sophisticated data acquisition systems with customizable amplifier configurations for cellular analysis, microelectrode array solutions for in vivo recordings, and in vitro systems for extracellular studies, in addition to a full suite of preclinical products. The company markets its offerings through direct sales teams, online channels, catalogs, and authorized distributors. Their diverse customer base includes research scientists within pharmaceutical and biotechnology companies, academic institutions (universities, colleges), hospitals, government laboratories, and contract research organizations. Products are sold under well-known brand names such as Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. Founded in 1901, Harvard Bioscience, Inc. is headquartered in Holliston, Massachusetts.